A number of clinical trials were conducted to investigate the combination of small molecule EGFR TKIs (including gefitinib, erlotinib and osimertinib) in NSCLC patients [89,90,91,92] (Table 1). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.